We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.
Department of Medicine

You are here

Melnick Laboratory: Critical Advances for the Treatment of non-Hodgkin Lymphoma Published in Cancer Cell

Dr. Ari Melnick

Dr. Ari Melnick, the Gebroe Family Professor of Hematology/Oncology, Division of Hematology and Medical Oncology, and colleagues have published critical findings on non-Hodgkin Lymphoma in Cancer Cell. Diffuse large B cell lymphomas (DLBCLs), which account for approximately one third of all non-Hodgkin lymphomas, were found to be addicted to an enzyme called SIRT3. It was discovered that this enzyme turbo-charges a metabolic process that supports the rapid growth of DLBCLs. In response to this finding, Dr. Melnick and team went on to develop an SIRT3-blocking compound that rapidly kills DLBCL cells in the culture dish and in mice.

It has been known that DLBCL cells carry differing sets of cancer-driving gene mutations. The team uncovered that the over-activity of SIRT3 in DLBCL is a core feature that occurs across all sets of gene mutation (genetic subtypes). Using the current treatments for DLBCL, about 40% of patients fail to respond or they relapse. Treatments for DLBCL have been challenging due to the differing sets of gene mutation. Dr. Melnick explains that the SIRT3-inhibtor approach has the potential to benefit many non-Hodgkin lymphoma patients “because it targets a feature of these lymphomas that is independent of their genetics.” This finding has been especially illuminating, as SIRT3 had generally been considered a tumor suppressor, not a tumor-driver.

In developing chemical compounds to inhibit SIRT3 activity, Dr. Melnick worked with Dr. Hening Lin, a Professor of Chemistry at Cornell University and co-senior author on the Cancer Cell publication. During this phase of the research, a compound was found (YC8-02) that showed no evident toxicity. The scientists also found that SIRT3 is not a critical element for normal functioning in noncancerous B cells. Thus, altogether, the path looks promising towards an SIRT3 inhibitor drug that would be relatively free of side effects.

Related Links

Weill Cornell Newsroom